XJ Fragmentomics Features
Ontology highlight
ABSTRACT:
INSTRUMENT(S): NA, Illumina NovaSeq 6000
ORGANISM(S): Homo sapiens
SUBMITTER: Miao Dang
PROVIDER: E-MTAB-16905 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:Prostate cancer (PCa) is one of the most common malignancies in men, with familial forms accounting for nearly 20% of cases. Early detection and risk stratification remain challenging, especially in individuals with a genetic predisposition. In this pilot study, we evaluated the feasibility and clinical relevance of an integrated multi-omic approach by performing whole-genome, strand-specific sequencing of circulating cell-free DNA (cfDNA) from eight patients with confirmed familial PCa. Through an integrated analysis pipeline, we identified 18,878 genetic variants, of which 2,276 were potentially pathogenic. Among these, 26 recurrent high-impact mutations—such as stop-gain and start-loss variants—were found in genes including MUC4, MCM9, and SKA3. Epigenomic profiling revealed widespread hypermethylation in these genes, suggesting transcriptional repression, while allele-specific methylation (ASM) was detected in TTC22, TEX51, WDR89, LAIR2, and SKA3, indicating functional interplay between somatic mutations and local epigenetic regulation. These findings demonstrate the potential of combining genetic and epigenetic data from cfDNA to uncover novel markers for improved stratification and personalized management of familial prostate cancer.
2026-06-15 | E-MTAB-15437 | biostudies-arrayexpress
Project description:This submission contains the data from https://www.biorxiv.org/content/10.1101/795047v2.full This dataset contains processed data of cell-free reduced representation bisulfite sequencing from 60 pediatric cancer samples, in order to classify them according to histopathological diagnosis. Files are provided in bismark coverage format. Samples were sequenced on a NextSeq 500.
2020-02-27 | E-MTAB-8770 | biostudies-arrayexpress
Project description:Plasma DNA from 558 malignancies, 263 benign and borderline tumors and 367 healthy control samples were collected and subjected to random short-gun whole genome sequencing.
2022-07-03 | E-MTAB-10934 | biostudies-arrayexpress
Project description:We carried out a genome-wide cfDNA methylation profiling study of pancreatic ductal adenocarcinoma (PDAC) patients by Methylated DNA Immunoprecipitation coupled with high-throughput sequencing (MeDIP-seq). Compared with healthy individuals, 775 differentially methylated regions (DMRs) located in promoter regions were identified in PDAC patients with 761 hypermethylated and 14 hypomethylated regions; meanwhile, 761 DMRs in CpG islands (CGIs) were identified in PDAC patients with 734 hypermethylated and 27 hypomethylated regions (p-value < 35 0.0001). 143 hypermethylated DMRs were further selected which were located in promoter regions and completely overlapped with CGIs. A total of 8 probes from 8 genes were found to fairly distinguish PDAC patients from the healthy individuals, including TRIM73, FAM150A, EPB41L3, SIX3, MIR663, MAPT, LOC100128977 and LOC100130148.
2020-10-29 | E-MTAB-9678 | biostudies-arrayexpress
Project description:As a non-invasive blood testing, the detection of cell-free DNA (cfDNA) methylation in plasma is raising increasing interest due to its diagnostic and biology applications. Although extensively used in cfDNA methylation analysis, bisulfite sequencing is less cost-effective. Through enriching methylated cfDNA fragments with MeDIP followed by deep sequencing, we aimed to characterize cfDNA methylome in cancer patients. In this study, we investigated the cfDNA methylation patterns in lung cancer patients by MeDIP-seq. MEDIPS package was used for the identification of differentially methylated regions (DMRs) between patients and normal ones. Overall, we identified 330 differentially methylated regions (DMRs) in gene promoter regions, 33 hypermethylation and 297 hypomethylation respectively, by comparing lung cancer patients and healthy individuals as controls. The 33 hypermethylation regions represent 32 genes. Some of the genes had been previously reported to be associated with lung cancers, such as GAS7, AQP10, HLF, CHRNA9 and HOPX. Taken together, our study provided an alternative method of cfDNA methylation analysis in lung cancer patients with potential clinical applications.
2019-03-31 | E-MTAB-7163 | biostudies-arrayexpress
Project description:This study aimed to evaluate the cost-effective and genome-wide cell-free reduced representation bisulfite sequencing (cfRRBS) method combined with computational deconvolution for effective disease monitoring in patients with esophageal adenocarcinoma (EAC). cfDNA methylation profiling with cfRRBS was performed on 162 blood plasma samples from 33 EAC cancer patients and 28 blood plasma samples from 20 healthy donors. In addition, for reproducibility testing purposes of the method, 9 plasma samples were re-prepped (library was re-made) and re-sequenced once (n=9) or twice (n=1). As a reference for the data deconvolution cfRRBS was performed on 7 EAC tumor tissue (FFPE) samples.
2024-12-04 | E-MTAB-14370 | biostudies-arrayexpress
Project description:The early detection of tissue and organ damage associated with autoimmune diseases (AID) has been identified as key to improve long-term survival, but non-invasive biomarkers are lacking. Elevated cell-free DNA (cfDNA) levels have been observed in AID and inflammatory bowel disease (IBD), prompting interest to use cfDNA as a potential non-invasive diagnostic and prognostic biomarker. Despite these known disease-related changes in concentration, it remains impossible to identify AID and IBD patients through cfDNA analysis alone. By using unsupervised clustering on large sets of shallow whole-genome sequencing (sWGS) cfDNA data, we uncover AID- and IBD-specific genome-wide patterns in plasma cfDNA in both the obstetric and general AID and IBD populations. Supervised learning of the genome-wide patterns allows AID prediction with 50% sensitivity at 95% specificity. Importantly, the method can identify pregnant women with AID during routine non-invasive prenatal screening. Since AID pregnancies have an increased risk of severe complications, early recognition or detection of new onset AID can redirect pregnancy management and limit potential adverse events. This method opens up new avenues for screening, diagnosis and monitoring of AID and IBD.
2022-09-14 | E-MTAB-11607 | biostudies-arrayexpress
Project description:In this study, we evaluated the effect of preservation agent on the effect of the methylation pattern of cell-free DNA. The methylation pattern was assessed with cell-free reduced representation sequencing (cf-RRBS). Blood was drawn from three healthy individuals (male and females between 24 and 50 years old). 15 tubes were drawn per healthy volunteer: 3x BD Vacutainer K2E EDTA spray tubes (REF 367525), 3x Streck Cell-Free DNA BCT tubes (catalogue number 218962), 3x PAXgene Blood ccfDNA tubes (catalogue number 768115), 3x Roche Cell-Free DNA Collection tubes (catalogue number 07785674001) and 3x Biomatrica LBgard blood tubes (SKU 68021-001), resulting in 45 samples in total. All 45 samples were sequenced on a NovaSeq6000. Samples are given as bismark coverage files (GRCh37).
2020-04-03 | E-MTAB-8858 | biostudies-arrayexpress
Project description:We evaluated whether targeted next-generation sequencing (NGS) using the Ion Torrent Personal Genome Sequencer of cfDNA could identify prognostic or predictive factors for overall survival (OS) or progression free survival (PFS) within a large cohort of patients with advanced lung adenocarcinoma enrolled in the GALAXY-1 trial.
2018-01-10 | E-MTAB-5749 | biostudies-arrayexpress
Project description:Previously, we demonstrated that high levels of mtDNA were functionally associated with “stemness” and aggressive phenotypic behaviours in human breast cancer cells, including spontaneous metastasis. More specifically, we showed that treatment with Alovudine induced mtDNA-depletion in MDA-MB-231 cells and prevented their ability to form colonies in vitro and metastasize in vivo. To better understand the underlying mechanism(s) and potentially develop a panel of protein biomarkers for metastasis, Alovudine- treated MDA-MB-231 cells were subjected to proteomics analysis. For comparison purposes, mtDNA-depletedrho(0) cells (MDA-MB-231 and MCF-7) were generated and also subjected to proteomics analysis. Intersection of these three distinct data sets revealed that a small number of proteins were commonly down-regulated in mtDNA-depleted rho(0) cells and Alovudine-treated cells. Remarkably, many of these nuclear-encoded mitochondrial genes (>20) were found to be genomically-amplified in human breast cancer metastatic samples. Therefore, the action of a single drug, namely Alovudine, was sufficient to effectively suppress the expression of a large number mitochondrial genes clinically associated with i) gene amplification and ii) cancer cell metastasis, in human breast cancer patients. These findings may have important clinical implications for the development of new therapeutics targeting cancer cell metastasis.
2026-07-16 | PXD077655 | Pride